Review of New Biomarkers in Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM — 8:00 AM, February 24, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx® for Prostate Cancer test was highlighted as one of several key advances in biomarker technology that aims to transform detection of prostate cancer and its subsequent management. In a review published in the February 2014 issue of ONCOLOGY, leading urologists, E. David Crawford, MD, Neal D. Shore, MD and co-author Karen Ventii, PhD, explain how an explosion in genomic analysis and interpretation of prostate cancer tissue has enabled discovery of new biomarkers, their integration into clinical practice, and clinical management of the disease.
Over 975,000 American men have a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man’s prostate. This approach leaves men at risk for undetected cancer, leading to a high rate of repeat biopsies, often on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer detects an epigenetic field effect or ‘halo’ associated with the presence of cancer at the DNA level. This “halo” around a tumor can be detected in prostate cells despite having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure.
“In the last few years, several new genomic biomarkers have emerged that can help guide clinicians on when to biopsy, whom to re-biopsy, and how to assist patients in their treatment decisions,” explained E. David Crawford, M.D, head of Urologic Oncology at the University of Colorado. “One such exciting test is ConfirmMDx for Prostate Cancer, an epigenetic assay to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. This test aids in improved risk stratification and allows us to reduce unnecessary repeat biopsies on men at low risk for prostate cancer.”
“Prostate cancer biomarkers should assist the clinician in improving risk assessment, reducing overtreatment, and providing more selective therapy for patients with high-risk disease,” noted Neal D. Shore, Medical Director of the Carolina Urologic Research Center, Myrtle Beach, South Carolina. “With new biomarkers like ConfirmMDx being integrated into the clinic, we are seeing clinical decision-making impact on patient care.”
MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
|Dr. Jan Groen, CEO
|Mike Sinclair (Media)
|Matt Clawson (Investors)
|Allen & Caron, Inc
|US: +1 949 812 6979
|UK: +44 20 7318 2955
|US: +1 949 474 4300
|BE: +32 4 364 20 70
|Cell:+44 7968 022075
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.